Circulating tumour DNA (ctDNA) testing is being used in RCTs across Australia and New Zealand to determine which patients are at risk of recurrence and their need for chemotherapy after bowel cancer resection. The RCTs in stage 2 and stage 3 bowel cancer follow on from earlier work which showed more than 80% of patients ...
‘This will be practice changing’: ctDNA testing shows who can avoid chemo
By Mardi Chapman
17 Oct 2018